慢性乙型病毒性肝炎治疗现状和展望.PDFVIP

传染病信息  2017年4月30日  第30卷  第2期  Infect Dis Info, Vol. 30, No. 2, April 30, 2017  ·65· ·导向与述评· 慢性乙型病毒性肝炎治疗现状和展望 王晶晶，陈国凤，廖家杰     [摘要]　HBV 感染是导致肝硬化和肝癌的主要原因，在过去 20 余年里，慢性乙型肝炎的治疗药物主要为干扰素和核苷 HBsAg （酸）类似物两大类，它们虽然能有效抑制病毒复制，但仍面临 清除率极低，安全停药难等问题，难以实现“临床治愈 （或 功能性治愈） ”。新型的血清标志物的出现为指导临床如何安全停用抗病毒药物开辟了新的途径，同时，治疗慢性乙型肝炎 的新型药物和生物制剂的崛起也给慢性乙型肝炎患者带来福音。     [关键词]　乙型肝炎；治疗；肝炎表面抗原；血清标志物     [中国图书资料分类号] R512.62　　　　[文献标志码]　A　　　　[文章编号] 1007-8134(2017)02-0065-06　    　　DOI:10.3969/j.issn.1007-8134.2017.02.001 Treatment of chronic hepatitis B infection: status quo and prospect * * WANG Jing-jing, CHEN Guo-feng , LIAO Jia-jie Second Liver Cirrhosis Diagnosis and Treatment Center, 302 Military Hospital of China, Beijing 100039, China * Corresponding author. CHEN Guo-feng, E-mail: guofengchen302@163.com; LIAO Jia-jie, E-mail: gkklau@ 　　[Abstract]　HBV infection is the major cause of liver cirrhosis and hepatocellular carcinoma. Over the past two decades, there are currently two classes of drugs approved for the treatment of hepatitis B: a finite antiviral and immunomodulatory treatment with peg- interferon or long-term treatment with nucleos (t) ide analogues.While they can potently suppress the virus replication, they have low rate of HBsAg clearance and common virological relapse after the cessation of therapy. So it is difficult to achieve clinical cure or complete cure. Now appearring of new biomarkers may open the way of stopping nucleos (t) ide analogues clinical use safely. Meanwhile various anti-HBV drugs or biological agents are in the development pipeline, which can bring hope to thousands of hepatitis B patients. 　　[Key words]　hepatitis B; treatment; HBsAg; biomarker HBV 3.5